-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Today, AstraZeneca announced the interim analysis results of the Phase III clinical trial of the new crown vaccine AZD1222 jointly developed by it and the University of Oxford.
Data show that AZD1222 is effective in preventing symptomatic COVID-19 by 79%, and it is 100% effective in preventing serious diseases and hospitalization.
Prevent COVID-19
Previously, AZD1222 in Phase III clinical trials in the United Kingdom, South Africa and Brazil, the data obtained is that the effectiveness of preventing symptomatic COVID-19 is 62.
thrombus
On the 19th, in response to the previous speculation that AstraZeneca's new crown vaccine caused "blood clotting", the WHO issued a safety statement for AstraZeneca's new crown vaccine.
In addition, the European newspaper also reported after vaccination while AstraZeneca vaccine with rare thrombotic thrombocytopenic symptoms, but not sure this is caused by the vaccine, the European Medicines Management Bureau has also not yet clear causal relationship.
management
At present, some European countries have resumed the vaccination, while some countries still have reservations.
AstraZeneca is expected to submit the vaccine to the FDA for approval in early April , and is expected to launch a production capacity of 30,000 doses after the approval is approved.
FDA leaves a message here
